351
Participants
Start Date
January 1, 2003
Primary Completion Date
November 1, 2005
Study Completion Date
November 12, 2013
CC-5013 plus dexamethasone
25 mg daily for 21 days every 28 days.
Dexamethasone plus Placebo
Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne
Wilhelminenspital, Vienna
CHU Saint-Luc, Brussels
Royal Prince Alfred Hospital, Camperdown
UZ Gasthuisberg, Leuven
Peter MacCallum Cancer Centre Divsion of Haematology/Medical Oncology, East Melbourne
The Royal Melbourne Hospital, Parkville
The Alfred Hospital, Prahran
Border Medical Oncology, Wodonga
Universitätsspital Zürich, Zurich
Zhitomir Regional Clinical Hospital, Zhytomyr
Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Torio
"Alexandras General Hospital of Athens", Athens
Universitaetsklinikum Charite, Berlin
Universitatsklinik ChariteMedizinische Fakultaet der HumboldtUniversitaet zu Berlin, Berlin
Azienda Ospedaliera San Martino, Genova
Cherkassy Regional Oncology Center, Cherkassy
Ospedale Niguarda Ca Granda, Milan
Policlinico San Matteo, Pavia
Hospital Universitario de la Princessa, Madrid
Hospital Doce de Octubre, Madrid
Clinica Universitaria de Navarra, Pamplona
Rambam Medical Center, Haifa
Policlinico Universitario a Gesttione diretta di Udine, Udine
Chu de Bordeaux Groupe Hospitalier Sud, Pessac
Hospital Universitario de Salamanca, Salamanca
Hospital Universtario Marques de Valdecilla, Santander
Policlinico Sant'Orsola-Malpighi, Bologna
Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Düsseldorf
Universitatsklinik Muenster Medizinische Klinik A, Münster
Dnepropetrovsk City Clinical Hospital #4, Dnipro
The Chaim Sheba Medical Center, Tel Litwinsky
CHU Nancy - Hopital Brabois, Vandœuvre-lès-Nancy
Hopital Claude Huriez, Lille
Klininkum der Johann-Wolfgang-Goethe-Universtat, Frankfurt am Main
Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv
Odess Regional Clinical Hospital, Odesa
Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V, Heidelberg
Universitaetsklinikum Tuebingen, Tübingen
Hopital Saint-Loius, Paris
Institute of Blood Pathology and Transfusion Medicine of the UAMS Hematology Department, Lviv
Institute of Blood Pathology and Transfusion Medicine of the UAMS, Lviv
Klinikum der Univeristact Muenchen, München
Universitaetsklinkum Erlangen, Erlangen
Box Hill Hospital, Box Hill
Frankston Hospital Oncology Research, Frankston
Royal Brisbane Hospital, Herston
Mater Public Hospital, South Brisbane
University Hospital of Salzburg St Johanns Spital, Salzburg
Centre Hospitalier Lyon Sud, Chemin Grand Revoyet
Centre Hospitalier Hotel-Dieu, Nantes
University Hospital GalwayHaematology Department, Galway
Hope Directorate Haematology Oncology Service St. James Hospital, Dublin
MidWestern Regional Hospital, Limerick
Hadassah University Hospital, Jerusalem
Kantonsspital St. Gallen, Sankt Gallen
CHU Purpan, Toulouse
Belfast City HospitalHaematology Department, Belfast
Univerita La Sapien, Roma
Institute of Internal Diseases University of Medicine, Gdansk
University School of Medicine, Lublin
Institute of Haematology and Blood Transfusion, Warsaw
Hospital Clinic, Barcelona
Sahlgrenska University Hospital Department of Hematology and Coagulation, Gothenburg
Kiev Bone Marrow Transplantation Center Bone Marrow Department, Kiev
Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev
University College Hospital Trust, London
Bristol Haematology and Oncology Centre, Bristol
Haematology Dept, 4th Floor Thomas Guy House, London
Lead Sponsor
Celgene
INDUSTRY